protein

Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2)

MBS2018573

0.01 mg

200 USD

Recombinant Protein

Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2)

Breast Cancer Susceptibility Protein 2 (BRCA2)

breast cancer type 2 susceptibility protein; Breast cancer type 2 susceptibility protein; breast cancer type 2 susceptibility protein; fanconi anemia group D1 protein; breast cancer 2 tumor suppressor; BRCA1/BRCA2-containing complex, subunit 2; breast and ovarian cancer susceptibility gene, early onset; truncated breast and ovarian cancer susceptibility protein 2; breast cancer 2, early onset; Fanconi anemia group D1 protein

BRCA2

BRCA2; BRCA2; FAD; FACD; FAD1; GLM3; BRCC2; FANCB; FANCD; PNCA2; FANCD1; BROVCA2; FACD; FANCD1

BRCA2_HUMAN

E Coli

3418

The target protein is fused with two N-terminal Tags, His-tag and T7-tag, its sequence is listed below. MGSSHHHHHH SSGLVPRGSH MASMTGGQQM GRGSEF- KST PDGTIKDRRL FMHHVSLEPI TCVPFRTTKE RQEIQNPNFT APGQEFLSKS HLYEHLTLEK SSSNLAVSGH PFYQVSATRN EKMRHLITTG RPTKVFVPPF KTKSHFHRVE QCVRNINLEE NRQKQNIDGH GSDDSKNKIN DNEIHQFNKN NSNQAAAVTF TKCEEEPLDL ITSLQNARDI QDMRIKKKQRQRVFPQPGSL YLAKTSTLPR ISLKAAVGGQ VPSACSH

> 95%

Supplied as lyophilized form in 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5% trehalose, and preservative.

Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP)

Organism: Homo sapiens (Human). Expression System: Prokaryotic expression. Residues: Lys2308~His2537 (Accession # P51587) with two N-terminal Tags, His-tag and T7-tag

Endotoxin Level: <1.0EU per 1ug (determined by the LAL method). Predicted Isoelectric Point: 9.7. Reconstitution: Reconstitute in sterile PBS, pH7.2-pH7.4.

About the Marker: Effective Size Range: 10kDa to 70kDa. Protein bands: 10kDa, 14kDa, 18kDa, 22kDa, 26kDa, 33kDa, 44kDa and70kDa. Double intensity bands: The 26kDa, 18kDa, 10kDa bands are at doubleintensity to make location and size approximation of proteins of interestquick and easy. Ready-to-use: No need to heat, dilute or add reducing agents before use.

119395734

NP_000050.2

NM_000059.3

P51587

30.0kDa

DNA Repair Pathway (105837); Double-Strand Break Repair Pathway (105861); FOXM1 Transcription Factor Network Pathway (137935); Fanconi Anemia Pathway (105895); Fanconi Anemia Pathway (377262); Fanconi Anemia Pathway (377128); Homologous DNA Pairing And Strand Exchange Pathway (105870); Homologous Recombination Repair Pathway (105862); Homologous Recombination Pathway (198890); Homologous Recombination Pathway (83046)

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, Dec 2008]

BRCA2: involved in double-strand break repair and/or homologous recombination. May participate in S phase checkpoint activation. Interacts with RAD51 and DSS1. Interacts with ubiquitinated FANCD2. Interacts with PALB2, enables the recombinational repair and checkpoint functions. Interacts with WDR16. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer and may underlie susceptibility to uveal melanoma. Protein type: Nuclear receptor co-regulator; DNA repair, damage; Tumor suppressor. Chromosomal Location of Human Ortholog: 13q12.3. Cellular Component: nucleoplasm; centrosome; protein complex; cytoplasm; BRCA2-MAGE-D1 complex; nucleus; secretory granule. Molecular Function: gamma-tubulin binding; H4 histone acetyltransferase activity; protein binding; histone acetyltransferase activity; protease binding; H3 histone acetyltransferase activity; single-stranded DNA binding. Biological Process: positive regulation of transcription, DNA-dependent; cytokinesis; cell aging; DNA repair; positive regulation of mitotic cell cycle; inner cell mass cell proliferation; oocyte maturation; regulation of cytokinesis; negative regulation of mammary gland epithelial cell proliferation; double-strand break repair via homologous recombination; response to UV-C; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; male meiosis I; nucleotide-excision repair; double-strand break repair; response to gamma radiation; replication fork protection; spermatogenesis; hemopoiesis; brain development; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; centrosome duplication; female gonad development; response to X-ray. Disease: Pancreatic Cancer, Susceptibility To, 2; Breast-ovarian Cancer, Familial, Susceptibility To, 2; Medulloblastoma; Breast Cancer; Prostate Cancer; Glioma Susceptibility 3; Tracheoesophageal Fistula With Or Without Esophageal Atresia; Fanconi Anemia, Complementation Group D1; Wilms Tumor 1

0.01 mg

200 USD

0.05 mg

430

0.1 mg

665